A system including a leadless pacemaker and a subcutaneous implantable cardioverter defibrillator that wirelessly communicate with each other was safe in patients at risk for fatal ventricular arrhythmias at 6 months, researchers reported. The interim 6-month results of the MODULAR ATP trial of the leadless pacing-defibrillator system (mCRM system, Boston Scientific) were presented at Heart
It s actually two leadless pacemakers, one atrial and the other ventricular, linked as if in a wireless network, that together maintained true AV synchronous pacing in a short-term study.
Abbott's AVEIR DR i2i IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker